Physician profile
Chander Arora
NPI 1316929094
$567.61
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $187.57 | 2019-2020 | |
| Pfizer INC. | $143.91 | 2019-2020 | |
| Grifols USA, LLC | $31.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.32 | 2019-2020 | |
| Lilly USA, LLC | $30.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.89 | 2020 | |
| Allergan, INC. | $24.63 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.44 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.35 | 2019 | |
| Amgen INC. | $12.75 | 2019 | |
| Sanofi Pasteur INC. | $11.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chander Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.